Unknown

Dataset Information

0

Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.

ABSTRACT: We report herein the discovery of exceptionally potent and orally bioavailable PROTAC AR degraders with ARD-2585 being the most promising compound. ARD-2585 achieves DC50 values of ≤0.1 nM in the VCaP cell line with AR gene amplification and in the LNCaP cell line carrying an AR mutation. It potently inhibits cell growth with IC50 values of 1.5 and 16.2 nM in the VCaP and LNCaP cell lines, respectively, and achieves excellent pharmacokinetics and 51% of oral bioavailability in mice. It is more efficacious than enzalutamide in inhibition of VCaP tumor growth and does not cause any sign of toxicity in mice. ARD-2585 is a promising AR degrader for extensive investigations for the treatment of advanced prostate cancer.

SUBMITTER: Xiang W 

PROVIDER: S-EPMC8855934 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.

Xiang Weiguo W   Zhao Lijie L   Han Xin X   Qin Chong C   Miao Bukeyan B   McEachern Donna D   Wang Yu Y   Metwally Hoda H   Kirchhoff Paul D PD   Wang Lu L   Matvekas Aleksas A   He Miao M   Wen Bo B   Sun Duxin D   Wang Shaomeng S  

Journal of medicinal chemistry 20210902 18

We report herein the discovery of exceptionally potent and orally bioavailable PROTAC AR degraders with ARD-2585 being the most promising compound. ARD-2585 achieves DC<sub>50</sub> values of ≤0.1 nM in the VCaP cell line with AR gene amplification and in the LNCaP cell line carrying an AR mutation. It potently inhibits cell growth with IC<sub>50</sub> values of 1.5 and 16.2 nM in the VCaP and LNCaP cell lines, respectively, and achieves excellent pharmacokinetics and 51% of oral bioavailability  ...[more]

Similar Datasets

Unknown Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
| S-EPMC10568492 | biostudies-literature
Unknown A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo.
| S-EPMC7498667 | biostudies-literature
Unknown Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood-Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2.
| S-EPMC9501899 | biostudies-literature
Unknown Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13.
| S-EPMC9876424 | biostudies-literature
Unknown Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1.
| S-EPMC7606109 | biostudies-literature
Unknown Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity <i>in vivo</i>.
| S-EPMC8148065 | biostudies-literature
Unknown Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with <i>MET</i> alterations.
| S-EPMC10326257 | biostudies-literature
Unknown Discovery of a potent BTK and IKZF1/3 triple degrader through reversible covalent BTK PROTAC development.
| S-EPMC9879287 | biostudies-literature
Transcriptomics Discovery of a Highly Potent and Selective HDAC3 and HDAC8 PROTAC Dual Degrader
2023-07-18 | GSE211758 | GEO
Unknown Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2.
| S-EPMC10901292 | biostudies-literature